AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

The Doctor Chooses, the Contract DecidesNarrow moat

Abbott Laboratories (ABT) — moat facet

Abbott's devices are chosen by doctors and bought by hospitals on contract; its filings say performance decides what sells and contracts decide the price.

In medical devices the customer is two people. A cardiologist or electrophysiologist chooses which catheter, valve clip or pacemaker to use; a hospital pays for it, usually under a contract. Abbott says "technological and performance features" and whether its products are included "under a contract" most affect which products are sold1, while "price controls, competition, and rebates most impact the net selling prices of products"2.

Abbott Medical Devices sales, Q2 2026 ($M)2,680United States3,173InternationalAbbott Q2 2026 earnings release, Medical Devices sales table
More than half of device sales are outside the US.

The two forces pull in different directions. The doctor's preference rewards Abbott's clinical evidence and training, which is why electrophysiology grew 13.4% on a comparable basis in the second quarter of 20263. The contract rewards price, which is why mature lines such as vascular grow slowly.

The United States is where this matters most. US Medical Devices sales were $2,680 million in the second quarter, up 8.0% on a comparable basis4, against international device sales of $3,173 million5. American hospitals buy through contracts that compare prices across suppliers.

Abroad, the buyer is often the state. Abbott sells to government agencies around the world6, and in China volume-based procurement has turned hospital purchasing into national tenders, which the Core Laboratory page covers.

Electrophysiology shows the doctor's side winning. US electrophysiology sales were $420 million in the second quarter of 2026, up 15.9%7, faster than any other US device line.

The US device lines spread widely. In the second quarter of 2026 US Rhythm Management rose 10.7%, Heart Failure 10.9% and Structural Heart fell 9.8%8, and US device sales for the first half were $5,203 million, up 7.4%9. Where doctors have a clear preference the lines grow; where the contract decides, they stall. Abroad, device sales were $6,189 million in the first half, up 14.2% reported10. US electrophysiology, where physician preference matters most, rose 14.8% in the half11, against 6.2% for US Vascular12. US Heart Failure sold $313 million in the quarter13.

Physician preference is the moat here, and the contract is its limit. Under 6% US comparable growth, with international growth intact, and American contracts are overriding the doctors' choices.

Moat trajectory: Holding steady

US Medical Devices +8.0% comparable in Q2 2026.

The number that tests this moat
Reported
US Medical Devices comparable growth, latest quarter
+8.0% (Q2 2026: $2,680M)

Whether physician preference still beats contract pricing at home; below 6% would mean it does not.

Source: Abbott Q2 2026 earnings release ↗
References
  1. ReportedAbbott says "technological and performance features" and whether its products are included "under a contract" most affect which products are sold, while "price controls, competition, and rebates most impact the net selling prices of products".
    Abbott Laboratories Form 10-K for 2025 (year ended 31 December 2025) - consolidated financial statements: income, taxes, cash flow, dividends, repurchases, debt, goodwill and the critical accounting policy on rebates. — FY2025 · publ. 20 February 2026 · source ↗
  2. ReportedAbbott says "technological and performance features" and whether its products are included "under a contract" most affect which products are sold, while "price controls, competition, and rebates most impact the net selling prices of products".
    Abbott Laboratories Form 10-K for 2025 (year ended 31 December 2025) - consolidated financial statements: income, taxes, cash flow, dividends, repurchases, debt, goodwill and the critical accounting policy on rebates. — FY2025 · publ. 20 February 2026 · source ↗
  3. ReportedThe doctor's preference rewards Abbott's clinical evidence and training, which is why electrophysiology grew 13.4% on a comparable basis in the second quarter of 2026.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Medical Devices sales by business, continuous glucose monitors, Amulet and TECTONIC. — Q2 2026 · publ. 16 July 2026 · source ↗
  4. ReportedUS Medical Devices sales were $2,680 million in the second quarter, up 8.0% on a comparable basis, against international device sales of $3,173 million.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Medical Devices sales by business, continuous glucose monitors, Amulet and TECTONIC. — Q2 2026 · publ. 16 July 2026 · source ↗
  5. ReportedUS Medical Devices sales were $2,680 million in the second quarter, up 8.0% on a comparable basis, against international device sales of $3,173 million.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Medical Devices sales by business, continuous glucose monitors, Amulet and TECTONIC. — Q2 2026 · publ. 16 July 2026 · source ↗
  6. ReportedAbbott sells to government agencies around the world, and in China volume-based procurement has turned hospital purchasing into national tenders, which the Core Laboratory page covers.
    Abbott Laboratories Form 10-K for 2025 (year ended 31 December 2025) - Item 1 and MD&A for Diagnostic Products: Core Laboratory, Rapid, Molecular and Point of Care, COVID-19 testing and China. — FY2025 · publ. 20 February 2026 · source ↗
  7. ReportedUS electrophysiology sales were $420 million in the second quarter of 2026, up 15.9%, faster than any other US device line.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Medical Devices sales by business, continuous glucose monitors, Amulet and TECTONIC. — Q2 2026 · publ. 16 July 2026 · source ↗
  8. ReportedIn the second quarter of 2026 US Rhythm Management rose 10.7%, Heart Failure 10.9% and Structural Heart fell 9.8%, and US device sales for the first half were $5,203 million, up 7.4%.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Medical Devices sales by business, continuous glucose monitors, Amulet and TECTONIC. — Q2 2026 · publ. 16 July 2026 · source ↗
  9. ReportedIn the second quarter of 2026 US Rhythm Management rose 10.7%, Heart Failure 10.9% and Structural Heart fell 9.8%, and US device sales for the first half were $5,203 million, up 7.4%.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Medical Devices sales by business, continuous glucose monitors, Amulet and TECTONIC. — Q2 2026 · publ. 16 July 2026 · source ↗
  10. ReportedAbroad, device sales were $6,189 million in the first half, up 14.2% reported.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - total sales, income statement, specified items, tax rate, guidance and the dividend. — Q2 2026 · publ. 16 July 2026 · source ↗
  11. ReportedUS electrophysiology, where physician preference matters most, rose 14.8% in the half, against 6.2% for US Vascular.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Medical Devices sales by business, continuous glucose monitors, Amulet and TECTONIC. — Q2 2026 · publ. 16 July 2026 · source ↗
  12. ReportedUS electrophysiology, where physician preference matters most, rose 14.8% in the half, against 6.2% for US Vascular.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Medical Devices sales by business, continuous glucose monitors, Amulet and TECTONIC. — Q2 2026 · publ. 16 July 2026 · source ↗
  13. ReportedUS Heart Failure sold $313 million in the quarter.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Medical Devices sales by business, continuous glucose monitors, Amulet and TECTONIC. — Q2 2026 · publ. 16 July 2026 · source ↗
Sources
Generated October 6, 2026